Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 436.

https://doi.org/10.1182/blood.V130.Suppl_1.436.436

Published: 2017

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

Journal Articles

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Leo Rasche, MD, Tobias Meissner, PhD, Grant Gershner, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Owen W. Stephens, Michael Bauer, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4372.

https://doi.org/10.1182/blood.V130.Suppl_1.4372.4372

Published: 2017

Journal Articles

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Meera Mohan, MD, Niels Weinhold, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Leo Rasche, MD, Jeffery R. Sawyer, Erming Tian, PhD MBA, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Maurizio Zangari, MD

Blood (2017) 130 (Supplement 1): 4373.

https://doi.org/10.1182/blood.V130.Suppl_1.4373.4373

Published: 2017

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

Molecular Subtypes of Plasma Cell Neoplasms with Circulating Neoplastic Plasma Cells

Anwar Rjoop, Soumya Pandey, Giovani Insuasti, MD, Rodolfo Lobo Henrich, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Gareth J. Morgan, MD PhD, Faith E Davies, MD, Daisy Alapat, MD

Blood (2017) 130 (Supplement 1): 4387.

https://doi.org/10.1182/blood.V130.Suppl_1.4387.4387

Published: 2017

Journal Articles

MAF and NF-κB Signaling Pathways Regulate Expression of APOBEC3B in Multiple Myeloma

Valeriy V Lyzogubov, MD PhD, Ruslana G. Tytarenko, MS, Cody Cody Ashby, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 4342.

https://doi.org/10.1182/blood.V130.Suppl_1.4342.4342

Published: 2017

Journal Articles

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Leo Rasche, MD, Carolina D. Schinke, MD, Daisy Alapat, MD, Grant Gershner, Sarah K Johnson, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, James E McDonald, BS, MD, Rohan Samant, MD, Edgardo Angtuaco, MD, Brian A Walker, PhD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4510.

https://doi.org/10.1182/blood.V130.Suppl_1.4510.4510

Published: 2017

Journal Articles

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Whitney Tevebaugh, James Douglas, MS, Brian A Walker, PhD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J. Morgan, MD PhD, Sarah K Johnson, PhD

Blood (2017) 130 (Supplement 1): 4392.

https://doi.org/10.1182/blood.V130.Suppl_1.4392.4392

Published: 2017

Journal Articles

MAFA Expression Promotes Proliferation of Myeloma Cells and Its Protein Stability Is Regulated By Proteasome Inhibitors

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Ichiro Hanamura, MD PhD, Brian A Walker, PhD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2017) 130 (Supplement 1): 4394.

https://doi.org/10.1182/blood.V130.Suppl_1.4394.4394

Published: 2017

Journal Articles

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Aneta Mikulasova, PhD, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Michael Bauer, PhD, Konstantimos Mavrommatis, PhD, Christopher P. Wardell, PhD, Matthew Trotter, PhD, Shayu Deshpande, Owen W. Stephens, Erming Tian, PhD MBA, Graham Jackson, Faith E. Davies, MD, Anjan Thakurta, PhD, Nikhil Munshi, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 65.

https://doi.org/10.1182/blood.V130.Suppl_1.65.65

Published: 2017

Journal Articles

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Gordon Cook, MD PhD, Kara-Louise Royle, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Anna Hockaday, Walter M Gregory, PhD, J Anthony Child, Faith E Davies, MD, Gareth J. Morgan, MD PhD, David Cairns, BSc, MSc, PhD, Graham Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 3063.

https://doi.org/10.1182/blood.V130.Suppl_1.3063.3063

Published: 2017

Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD

Blood (2017) 130 (Supplement 1): 904.

https://doi.org/10.1182/blood.V130.Suppl_1.904.904

Published: 2017

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

Faith E. Davies, MD, Rohan Samant, MD, Thomas J. Eluvathingal, Leo Rasche, MD, Amy Buros, PhD, Kristen Schemel, Edgardo J. Angtuaco, MD, Rudy L. Van Hemert, MD, Manoj Kumar, MD, James E McDonald, BS, MD, James A. Ntambi, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Niels Weinhold, PhD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 5375.

https://doi.org/10.1182/blood.V130.Suppl_1.5375.5375

Published: 2017

Journal Articles

Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study

Charlotte A Bradbury, PhD MD FRCPath, FRCP, MSc, Matthew W Jenner, Alina Striha, MSc, Gordon Cook, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, John R Jones, MD, David Cairns, BSc, MSc, PhD, Anna Hockaday, Andrea Paterson, Mark T Drayson, MD PhD, Roger G Owen, MD, Martin F Kaiser, MD, Walter M Gregory, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Graham H Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 553.

https://doi.org/10.1182/blood.V130.Suppl_1.553.553

Published: 2017

Journal Articles

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Tarun K. Garg, PhD, Katie Stone, BS, Amy Greenway, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Hing C Wong, PhD, Emily K Jeng, Niraj Shrestha, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Frits van Rhee, MD PhD

Blood (2017) 130 (Supplement 1): 5452.

https://doi.org/10.1182/blood.V130.Suppl_1.5452.5452

Published: 2017

Journal Articles

Identification of Novel Oncogenes and Tumor Suppressor Genes in Newly Diagnosed Multiple Myeloma

Brian A Walker, PhD, Christopher P. Wardell, PhD, Konstantimos Mavrommatis, PhD, Cody Cody Ashby, PhD, Michael Bauer, PhD, Mehmet Kemal Samur, PhD, Fadi Towfic, PhD, Maria Ortiz, Erin Flynt, PhD, Matthew Trotter, PhD, Anjan Thakurta, PhD, Nikhil Munshi, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 60.

https://doi.org/10.1182/blood.V130.Suppl_1.60.60

Published: 2017

Journal Articles

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Christopher P. Wardell, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2017) 130 (Supplement 1): 1790.

https://doi.org/10.1182/blood.V130.Suppl_1.1790.1790

Published: 2017

Journal Articles

Deconvolution of the Immune Microenvironment Can Predict the Outcome of Myeloma Patients and Inform Potential Intervention Strategies

Samuel Danziger, PhD, Andrew P Dervan, Frank Schmitz, MD PhD, Brian A Walker, PhD, Wilbert Copeland, PhD, Alison Fitch, BS, Kathryn Newhall, PhD, Cody Cody Ashby, PhD, Michael Bauer, PhD, Bart Barlogie, MD PhD, Teri Foy, PhD, Matthew Trotter, PhD, Rob Hershberg, MD PhD, Alexander Ratushny, PhD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 1751.

https://doi.org/10.1182/blood.V130.Suppl_1.1751.1751

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Molecular Subtypes of Plasma Cell Neoplasms with Circulating Neoplastic Plasma Cells

MAF and NF-κB Signaling Pathways Regulate Expression of APOBEC3B in Multiple Myeloma

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

MAFA Expression Promotes Proliferation of Myeloma Cells and Its Protein Stability Is Regulated By Proteasome Inhibitors

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

A Comparison of PET-CT to Whole Body Diffusion Weighted MRI in the Diagnosis of Plasma Cell Dyscrasias

Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Identification of Novel Oncogenes and Tumor Suppressor Genes in Newly Diagnosed Multiple Myeloma

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Deconvolution of the Immune Microenvironment Can Predict the Outcome of Myeloma Patients and Inform Potential Intervention Strategies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only